Science, Scale, and Skills: What’s Fueling the $30 B Cell & Gene Therapy CDMO Market—and Who’s Poised to Win

By: Chris Frew, CEO

Despite headwinds in the industry over the past few years, the Cell & Gene Therapy (CGT) CDMO sector has moved from niche to necessity. With more than 3,500 CGT therapies in development and market forecasts projecting over $30 billion in CDMO value by 2030, it’s clear that the CGT industry continues to dominate attention and growth. Analysts further forecast a climb to US $74 billion by 2034—a CAGR of ~28 percent. (Precedence Research) This surge is propelled by a swelling clinical pipeline, supportive regulators, and record capital outlays for new capacity. Yet bricks and bioreactors alone are not enough.

But this isn’t just a story about science. It’s a story about execution.

In my work helping CDMOs grow through smart hiring and workforce strategy, I’ve seen one truth stand out: The CDMOs best positioned to win in this space are those investing equally in talent, infrastructure, and operational excellence. Here’s what’s shaping the market — and how those that master “Science, Scale, and Skills” will lead the next chapter.

1 | Market Dynamics: Growth Drivers

Two converging forces—clinical momentum and manufacturing innovation—are redefining demand curves. More than 4,000 gene, cell, and RNA therapies are now in active development, a five-fold jump in ten years, driving unprecedented need for vector, plasmid, and cell-processing capacity. ASGCT Regulators are responding in kind: the U.S. FDA projects 10–20 CGT approvals every year by 2025, up from single digits just a few years ago, signaling a streamlined path from IND to BLA. U.S. Food and Drug Administration

Meanwhile, automation, closed-system bioreactors, and AI-driven scheduling have moved from pilot to plant-wide deployment. OmniaBio’s Ontario facility—the largest dedicated CGT CDMO in Canada—uses machine-learning algorithms to optimize run planning and predictive maintenance, illustrating how digital infrastructure is becoming a competitive moat. BioProcess International

Key data points

2 | Strategic Consolidations & M&A

Private-equity sponsors and strategics are stitching together end-to-end service platforms. In 2025, Altaris Capital agreed to buy WuXi Advanced Therapies’ U.S./U.K. cell-therapy business and closed a separate deal for Minaris Regenerative Medicine, creating a trans-Atlantic autologous powerhouse. AltarisMinaris Regenerative Medicine

Big-ticket exits continue: Novo Holdings is finalizing its US $16.5 B purchase of Catalent, re-orienting portions of the network to high-margin GLP-1 fill-finish while slimming CGT exposure. Fierce PharmaReuters Elsewhere, RoslinCT + Lykan, Recipharm’s ReciBioPharm roll-up, and SK pharmteco’s one-brand strategy aim to harmonize quality systems and simplify client contracting. Roslin CTRecipharmSK Pharmteco

Notable 2024-25 deals

  • Altaris ➜ WuXi Advanced Therapies (pending) & Minaris (closed)

  • Novo Holdings ➜ Catalent (US $16.5 B)

  • RoslinCT × Lykan Bioscience merger

  • Recipharm ➜ GenIbet, Vibalogics, Arranta Bio → “ReciBioPharm”

  • SK pharmteco unified its legacy brands under one CGT CDMO umbrella

3 | New Entrants & Capacity Expansions

While consolidation grabs headlines, specialist start-ups are filling capability gaps. Vector Biomed debuted in 2023 to tackle vector bottlenecks with algorithm-optimized lentiviral production, pledging a portion of capacity for lower-income markets. Kincell Bio came out of stealth focused on agile, small-batch cell therapy runs, targeting emergent biotech needs.

Green-field builds continue apace: Cellipont Bioservices opened a Texas facility designed for seamless clinical-to-commercial scale-up, while Pharmaron Biologics is investing £151 M to quadruple viral-vector capacity in Liverpool with U.K. government backing. OmniaBio’s AI-enabled plant further diversifies geographic risk and establishes Canada as a CGT manufacturing node.

Selected additions (2024-25)

  • Cellipont Bioservices | New Woodlands, TX CGT site

  • Pharmaron Biologics | £151 M Liverpool expansion

  • OmniaBio | 470,000 ft² Ontario flagship (AI integrated)

  • Vector BioMed | Algorithm-driven lentiviral vectors (MD)

  • Kincell Bio | Agile cell-therapy model (FL)

4 | Technology & Strategic Partnerships

CDMOs are formalizing innovation lanes. AGC Biologics launched a dedicated Cell & Gene Technologies Division in April 2025, anchoring proprietary vector platforms (ProntoLVV™, BravoAAV™) and single-use suites under one leadership team for faster capex decisions. AGC Biologics

Partnerships with academia extend reach upstream. Charles River Laboratories and the Gates Institute (Univ. of Colorado Anschutz) are codeveloping GMP lentiviral vectors for next-gen CAR-T programs, locking in future commercial supply while derisking early CMC work.

Technology highlights

  • Single-use, closed-system bioreactors standardizing for Phase III + commercial

  • AI scheduling/predictive maintenance (OmniaBio, others)

  • Hybrid academic-CDMO R&D models (Charles River × Gates Institute)

  • Platform vector libraries (AGC’s ProntoLVV™, BravoAAV™; Vector BioMed algorithms)

5 | The Talent Imperative

Facility expansion announcements are often followed by double-digit vacancy rates in MS&T, QA, and automation engineering. Industry salary surveys put critical-role vacancy above 15 % for many CGT CDMOs, lengthening tech-transfer timelines and elevating deviation risk. (2024 BioPlan survey).

Leading CDMO operators treat workforce as cap-ex, budgeting early for site-specific training centers of excellence, workforce development partnerships, and strategic talent pipeline initiatives that span from techs to execs. Strategic partnerships with community colleges in Philadelphia, RTP, and Maryland are producing operator-ready cohorts, while fractional-expert platforms like BioBuzz’s talent lab supply surge talent for validation or pre-inspection remediation. CDMOs that articulate mission-driven culture and clear promotion tracks report materially better retention.

Talent priorities

  • High-need roles: Process-development scientists, MS&T engineers, QA/QC directors, automation & data-science specialists

  • Pipelines: Boot-camps, community-college certificates, university consortia

  • Flexible models: Fractional executives, project-based validation teams, AI-enabled talent marketplaces

6 | Workforce Genetics Is the Talent Engine Behind Tomorrow’s CGT CDMOs

The data are unambiguous: the CDMOs that will dominate the next decade of cell- and gene-therapy manufacturing are those that align science, scale — and above all, skills. State-of-the-art suites and digital twins lose their edge the moment a critical MS&T engineer, QA director, or automation lead is missing from the org chart. Workforce Genetics was built to solve exactly that bottleneck.

A purpose-built CGT talent partner

  • Deep sector focus. Our exclusive work in life-science manufacturing, with an emphasis on advanced-therapy platforms, means every search starts with a pre-vetted network of vector, viral-process, and cell-handling specialists.

  • Full life-cycle coverage. From executive search and retained recruitment to surge project teams and fractional experts, we align talent strategy with each phase of your facility build-out and tech-transfer timeline.

  • Data-driven speed. Proprietary market-mapping tools and compensation benchmarks let us reduce time-to-hire without sacrificing fit — a critical advantage when vacancy risk can delay batch release by weeks.

Amplified by BioBuzz
Through our partnership with BioBuzz, we tap a community of 40,000+ life-science professionals, regional events, and real-time market intelligence. That ecosystem not only expands candidate reach but also strengthens employer branding, helping CDMOs become magnets for top scientists, engineers, and operational leaders.

Ready for what’s next
As CGT pipelines mature from clinical promise to commercial reality, Workforce Genetics stands ready to keep your headcount trajectory in lock-step with capacity growth, regulatory milestones, and investor expectations. Whether you are consolidating global sites, green-fielding a modular GMP facility, or scaling a newly acquired platform, we provide the talent architecture that turns bricks and bioreactors into on-time, in-spec product.

Let’s build the workforce that will power the next wave of transformative therapies.
Visit workforcegenetics.com or contact us at matthew@workforcegenetics.com to start the conversation.

Conclusion

The CGT CDMO marketplace is expanding at break-neck speed, but capital and capacity alone will not crown the champions. Value will accrue to organizations that balance science (deep modality know-how), scale (global, digitally enabled infrastructure), and skills (an engaged, specialized workforce). CDMOs that integrate these three pillars are poised to become indispensable partners to the innovators developing tomorrow’s transformative therapies.  CDMOs that combine scientific depth, industrial scale, and talent-centric execution are the ones positioned to capture the next decade of growth.

References

  1. Precedence Research, Cell & Gene Therapy CDMO Market Size 2025-2034 Precedence Research
  2. ASGCT/Citeline, Q1 2024 Therapy Landscape ASGCT
  3. FDA Press Release (Marks & Gottlieb), 2019 forecast 10-20 approvals U.S. Food and Drug Administration
  4. BioProcess Intl., “OmniaBio Opens Largest CGT CDMO Facility” BioProcess International
  5. Altaris press releases on WuXi AT & Minaris deals AltarisMinaris Regenerative Medicine
  6. FiercePharma & Reuters on Novo/Catalent acquisition Fierce PharmaReuters
  7. RoslinCT-Lykan merger note Roslin CT
  8. Recipharm advanced-therapy integration Recipharm
  9. SK pharmteco brand unification SK Pharmteco
  10. Vector-BioMed launch release Vector Biomed
  11. Kincell Bio & Charles River–Gates links Kincell Bio
  12. Cellipont Bioservices TX site Cellipont Bioservices
  13. Pharmaron £151 M Liverpool expansion Pharmaron
  14. AGC Biologics Cell & Gene Division launch AGC Biologics